A Study of Preimplantation Genetic Screening With Next Generation Sequencing Technology on Advanced Age Women

Infertility Clinical Trial

Official title:

A Prospective Randomized Controlled Study of Preimplantation Genetic Screening With Next Generation Sequencing Technology on Advanced Age Women

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02868528
• Other study ID #: KYXM-201603
• Status: Terminated
• Phase: N/A
• Start date: September 23, 2016
• Est. completion date: August 2019

Study information

• Verified date: March 2020
• Source: Reproductive & Genetic Hospital of CITIC-Xiangya
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

With the development of society, more and more aged pregnant women because of various reasons, their abnormality rate of egg chromosome was higher than that of young women, then the abnormality rate of embryo chromosome is higher too, so the pregnancy rate in aged women is lower, abortion rate is higher. In order to improve the pregnancy rate in aged women, cut down their abortion rate 、fetal birth with abnormal chromosome, and the risk of pregnancy termination after the prenatal diagnosis, reduce their pain of body and mind, the investigators will carry out this study. This is a prospective randomized controlled study of preimplantation genetic screening with Next generation sequencing technology. The embryos with more developmental potential and normal chromosomes should be selected. There is no related studies in Chinese. Most international research are limited to fluorescence in situ hybridization (FISH) technique, not on the embryo chromosome comprehensive screening. So there is no evidence of the effects of PGS on advanced age women.

This study is to compare the outcomes between the advanced age women with two methods respectively. After blastocyst culture, blastocysts will be transferred in the control group. In the Preimplantation Genetic Screening (PGS) group, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with Next generation sequencing（NGS） technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred. The investigators expect that, in PGS group live birth rate 、cancellation rate and pregnancy rate are higher than in control group; abortion rate is lower than that of the control group.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 124
• Est. completion date: August 2019
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 37 Years to 44 Years

Eligibility

Inclusion Criteria:

• Premenopausal females, age =37 years =44 years

• Have given birth to a healthy baby

• Bilateral ovaries

• Antral follicle count(AFC)=10,and Anti Mullerian Hormone (AMH)=2.0 ng/ml

Exclusion Criteria:

• Endometriosis disease

• Intrauterine adhesions history; intrauterine membrane polyp, tuberculosis and inflammation,

• Uterine malformation, multiple uterine myoma, uterine intramural myoma >3cm, submucous myoma;

• Unprocessed hydrosalpinx

• Adverse reproductive history; greater than or equal to 2 times history of unexplained abortion

• Chromosomal abnormalities or other genetic disease

• Infertility caused by male factors, such as puncture testicular, SRT did not see the class A and class B sperm

• Without high quality embryos in past controlled ovarian hyperstimulation (COH)cycles.

• Patients with poor ovarian response, the standard of poor ovarian response accords with Bolognacriteria standard, that is at least meet 2 among the following 3:

1. . Elder years (=40 years) or have other known inherited or acquired risk factors that may reduce follicle.

2. .History of cancellation of the cycles because of less than 3 follicular development, or history of egg number less than 4 after at least using Follicle-Stimulating Hormone(FSH) 150IU once a day.

3. .Ovarian reserve function test abnormalities, including sinus follicle number less than 5-7 AFC or AMH less than 0.5 to 1.1 ng/ml

Related Conditions & MeSH terms

• Infertility

Intervention

Genetic:
• chromosome screening with NGS technology

Locations

Country	Name	City	State
China	Reproductive & Genetic Hospital of CITIC-XIANGYA	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Reproductive & Genetic Hospital of CITIC-Xiangya

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	live birth rate		At birth
Secondary	cancellation rate		Up to the day of embryo transferred
Secondary	Pregnancy Rate		Up to 28th day after embryo transferred
Secondary	abortion rate		Through pregnancy period,average 10 months